Target intelligence / Profile preview

Serrate RNA effector molecule homolog (SRRT)

Target
SRRT
Molecular classification
RNA-binding protein, Adaptor/scaffold protein, Ribonucleoprotein complex component
01

Overview

Serrate RNA effector molecule homolog (SRRT, also known as ARS2) is a nuclear RNA-binding protein encoded by the human SRRT gene. It acts as a mediator between the mRNA cap-binding complex and primary microRNA processing machinery, supporting the delivery and stability of capped precursor miRNAs for RNAi gene silencing. SRRT/ARS2 also assists cell cycle progression around S phase and is crucial for neural stem cell maintenance by activating SOX2 transcription. The protein can modulate cellular sensitivity to arsenic but does not directly confer arsenic resistance in humans. Diseases linked with SRRT dysfunction include cerebral arteriopathy with subcortical infarcts and leukoencephalopathy and spondylocostal dysostosis. It functions mainly as a scaffold, binding capped RNAs and recruiting elements of the RNA processing and decay machinery. No drugs are currently available that target SRRT directly.

Other names
ARS2Arsenite-resistance protein 2Arsenite resistance proteinASR2Asr2SerrateArsenate resistance protein 2Arsenate resistance protein ARS2
02

Mechanism of action

Not applicable; no known drugs specifically modulate this protein directly. The molecule acts as a platform and scaffold for RNA-processing machinery and cap-binding complex.

03

Biological functions

RNA-mediated gene silencing (RNAi), especially miRNA pathwayPrimary microRNA (miRNA) processingRNA bindingCell cycle progression (especially S phase)Neural stem cell self-renewal (via SOX2 transcriptional activation)RNA metabolism (production and decay)
04

Disease associations

Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathySpondylocostal dysostosisArsenic sensitivity modulation
05

Safety considerations

None specific for therapeutic targeting; manipulating RNA processing platforms could have broad and unpredictable effects on gene expression, raising theoretical challenges for drug discovery.
06

Interacting drugs

None known; there are no established drugs that directly target SRRT/ARS2
07

Biomarkers

None established for routine patient use; however, SRRT/ARS2 expression or mutation may be relevant in certain research or rare genetic disease contexts (e.g., cerebral arteriopathy or spondylocostal dysostosis).

Beyond the preview

Go deeper on Serrate RNA effector molecule homolog (SRRT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serrate RNA effector molecule homolog (SRRT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call